Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Ann Hematol. 2022 Mar;101(3):717-719. doi: 10.1007/s00277-021-04584-y. Epub 2021 Jul 26.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • BNT162 Vaccine / administration & dosage
  • BNT162 Vaccine / adverse effects*
  • BNT162 Vaccine / immunology
  • Biomarkers
  • COVID-19 / prevention & control*
  • Female
  • Humans
  • Platelet Count
  • Purpura, Thrombotic Thrombocytopenic / diagnosis*
  • Purpura, Thrombotic Thrombocytopenic / etiology*
  • SARS-CoV-2* / immunology
  • Symptom Assessment
  • Vaccination / adverse effects

Substances

  • Biomarkers
  • BNT162 Vaccine

Supplementary concepts

  • Thrombotic thrombocytopenic purpura, acquired